Glutathione 1500mg Review

Glutathione (GSH) occupies a singular position in cellular biochemistry. It is the most abundant low-molecular-weight thiol in mammalian cells, present at millimolar concentrations in virtually every tissue, and it functions simultaneously as a direct antioxidant, a co-substrate for detoxifying enzymes, and a master regulator of redox-sensitive signaling pathways. ^[1] Decades of academic research have linked declining intracellular GSH levels to aging phenotypes, neurodegeneration, metabolic dysfunction, and impaired immune surveillance, making it one of the most studied molecules in oxidative biology. ^[2]

Apollo Peptide Sciences lists Glutathione 1500mg as a large-format research vial designed for multi-experiment laboratory workflows. At $70.00 per vial, the price-per-milligram is competitive within the research-peptide market, and the 1500 mg mass allows researchers to run extended in-vitro or ex-vivo protocols without frequent reordering. This review evaluates the compound's chemistry, documented mechanisms, published efficacy data, pharmacokinetic profile, purity expectations, and how it situates among related antioxidant tripeptides available to research programs.

The editorial team reviewed peer-reviewed literature indexed on PubMed, cross-referenced the available vendor CoA documentation, and compared formulation details against accepted biochemical standards. No product samples were tested independently for this review cycle; researchers are encouraged to request third-party mass-spectrometry verification before use, as outlined in the purity section below.

Editor's Verdict

Scoring the compound on the dimensions most relevant to research utility:

• Chemical identity confidence: Excellent. GSH has a fully resolved crystal structure, well-established HPLC retention profile, and precise mass of 307.32 g/mol.
• Mechanistic depth: Extensive. Four converging enzyme families (glutathione peroxidases, S-transferases, reductases, and gamma-glutamyltransferases) are characterized to atomic resolution.
• Evidentiary base: Strong, though predominantly animal or cell-culture data for the highest doses. Human bioavailability trials exist but remain methodologically heterogeneous.
• Vendor value: Competitive at $0.047/mg for a compound whose synthesis is technically demanding at scale.

Specifications

What It Is: Chemistry, Origin, and Structural Detail

Biosynthesis and Evolutionary Context

Glutathione is synthesized de novo in virtually all eukaryotic cells through a two-step enzymatic process. The first step couples glutamate and cysteine to form gamma-glutamylcysteine, catalyzed by glutamate-cysteine ligase (GCL, also known as gamma-glutamylcysteine synthetase). The second step appends glycine via glutathione synthetase (GS), yielding the tripeptide gamma-L-glutamyl-L-cysteinyl-glycine. ^[3] The GCL reaction is rate-limiting and subject to negative feedback by the product, making intracellular GSH concentration tightly self-regulated at physiological steady state.

The defining chemical feature of GSH is its unusual gamma-peptide bond connecting the glutamate residue to cysteine. Standard proteases recognize alpha-peptide bonds and thus cannot cleave GSH intracellularly, explaining why the molecule achieves millimolar concentrations (typically 1-10 mM in the cytoplasm and 10-15 mM in mitochondria) without turnover by conventional proteolytic machinery. ^[4] This resistance to intracellular proteolysis is a primary reason GSH functions as a stable redox buffer rather than a transient signaling molecule.

Evolutionary conservation of the GSH biosynthetic pathway across fungi, plants, and animals suggests the molecule was selected early in aerobic life as a primary defense against reactive oxygen species (ROS) generated by mitochondrial electron transport. Organisms that have lost GCL function cannot survive in aerobic environments without exogenous thiol supplementation, underscoring the molecule's indispensable role. ^[3]

Chemical Identity and Redox States

The thiol group (-SH) on the cysteine residue is the molecule's chemically active center. Under oxidizing conditions, two GSH molecules undergo disulfide bond formation to generate glutathione disulfide (GSSG), a reversible reaction regenerated by glutathione reductase (GR) using NADPH as a reductant. ^[1] The GSH:GSSG ratio therefore serves as a direct biochemical readout of cellular redox status: ratios above 100:1 indicate a reduced, healthy redox environment; ratios below 10:1 are associated with oxidative stress phenotypes. ^[5]

Beyond the GSH/GSSG couple, cysteine can form mixed disulfides with protein cysteines (glutathionylation), a post-translational modification that protects critical active-site residues during oxidative bursts and modulates enzyme activity. Glutathionylation of key glycolytic enzymes, kinases, and transcription factors is now recognized as a reversible regulatory mechanism analogous to phosphorylation, adding a layer of functional complexity beyond simple antioxidant buffering. ^[6]

The oxidized form GSSG represents a quality indicator in research vials. A vial exhibiting a yellowing color or off-odor should be tested for GSH:GSSG ratio before use, as partial oxidation during shipping or improper storage can substantially alter experimental outcomes in redox-sensitive assays.

Synthetic Production for Research Vials

Commercial research-grade GSH is produced by microbial fermentation (predominantly using engineered yeast or bacteria overexpressing GCL and GS) or by chemical synthesis via solid-phase or solution-phase peptide coupling. Fermentation routes are preferred at large scale because they yield the correct L,L stereochemistry without epimerization risk and avoid the need for protecting-group chemistry that could leave trace contaminants. The 1500 mg vial format from Apollo Peptide Sciences represents a scale consistent with fermentation production rather than bespoke peptide synthesis, and the $0.047/mg price point aligns with that production route. Researchers should confirm with the vendor whether fermentation or chemical synthesis was used, as the impurity profiles differ and matter for high-sensitivity mass-spectrometry assays.

Mechanism of Action

Direct Radical Scavenging and Redox Buffering

The reduced thiol of GSH donates a hydrogen atom to quench a wide range of reactive oxygen species: hydroxyl radicals, superoxide anion, hydrogen peroxide, lipid peroxyl radicals, and peroxynitrite. ^[5] This scavenging occurs non-enzymatically through the radical chain-termination chemistry central to antioxidant biology. Each GSH molecule donates one hydrogen atom and becomes a glutathionyl radical (GS-), which then rapidly dimerizes to GSSG. The regeneration of GSH from GSSG by glutathione reductase, powered by NADPH derived from the pentose phosphate pathway, completes the cycle.

At high cellular GSH concentrations (greater than 5 mM), the rate of non-enzymatic scavenging becomes significant relative to enzymatic mechanisms, making concentration maintenance a quantitatively important variable. Tissue-specific differences in GSH concentration partly explain differential susceptibility to oxidative injury: hepatocytes maintain the highest concentrations (up to 10 mM), while neurons operate at lower steady-state levels (0.5-2 mM) and are therefore more vulnerable to ROS bursts. ^[7]

Glutathione Peroxidase (GPx) Co-Substrate Function

Glutathione peroxidases (GPx1-GPx8 in mammals) use GSH as the obligate electron donor to reduce hydrogen peroxide and organic hydroperoxides to water and the corresponding alcohol, respectively. ^[8] GPx1, the cytoplasmic and mitochondrial isoform, accounts for the bulk of peroxide clearance in most cell types. GPx4, expressed highly in testes and neurons, specifically reduces phospholipid hydroperoxides and is the gatekeeper enzyme preventing ferroptosis, a form of iron-dependent oxidative cell death now implicated in ischemia-reperfusion injury and neurodegeneration. ^[9]

From a research perspective, GSH concentration is frequently the rate-limiting factor for GPx-mediated peroxide clearance when cells are challenged with oxidative stressors. Adding exogenous GSH to cell culture media does not directly replicate intracellular GSH elevation because of plasma membrane impermeability; however, cell-permeable GSH precursors (N-acetylcysteine) or liposomal GSH formulations are used to model the consequences of intracellular GSH repletion. ^[10]

Glutathione S-Transferase (GST) Conjugation

The glutathione S-transferases (GSTs: alpha, mu, pi, theta classes, plus microsomal MAPEG family) catalyze nucleophilic addition of the GSH thiol to electrophilic substrates, the primary mechanism for detoxifying reactive metabolites of drugs, carcinogens, environmental pollutants, and lipid peroxidation products such as 4-hydroxynonenal (4-HNE) and malondialdehyde. ^[11] The resulting glutathione conjugates are exported from cells by multi-drug resistance protein transporters (MRP1/ABCC1, MRP2/ABCC2) and subsequently processed via the mercapturic acid pathway to urinary N-acetylcysteine conjugates.

GST activity is a major determinant of drug metabolism phenotype. Cancer cells frequently overexpress GST-pi as a resistance mechanism against platinum-based chemotherapy and electrophilic alkylating agents. Conversely, insufficient GST capacity, sometimes due to GSH depletion, is associated with organ injury from acetaminophen overdose, in which the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) saturates GSH reserves and begins alkylating hepatic proteins. ^[12] This toxicology model is one of the most studied GSH-depletion paradigms in the literature and provides strong causal evidence for GSH's protective function.

Gamma-Glutamyltransferase (GGT) and Extracellular Turnover

On the outer plasma membrane and in tissues such as the kidney brush border, gamma-glutamyltransferase (GGT) cleaves the gamma-glutamyl bond of GSH to release glutamate and cysteinylglycine. This reaction initiates a transpeptidation cycle (the gamma-glutamyl cycle) that contributes amino acid transport and allows recovery of GSH-derived cysteine from extracellular pools. ^[13] GGT is clinically relevant because elevated serum GGT correlates with liver disease and oxidative stress burden. In research contexts, GGT activity measurement is used to estimate GSH turnover rates in tissue preparations.

Redox-Sensitive Signaling Modulation

Beyond direct antioxidant chemistry, GSH influences transcription factor activity through the glutathionylation of reactive cysteines in proteins including NF-kB, AP-1, Nrf2, and p53. ^[6] The Nrf2-KEAP1 axis is particularly well-studied: oxidative conditions oxidize critical KEAP1 cysteines, disrupting the KEAP1-mediated ubiquitination of Nrf2, allowing Nrf2 to translocate to the nucleus and transcribe a broad antioxidant gene program that includes GCL and GS themselves (a feed-forward amplification loop). ^[14] GSH depletion therefore has compounding effects: it both reduces direct scavenging capacity and impairs the signal that would upregulate GSH biosynthesis.

Tissue Distribution and Compartmentalization

GSH is not uniformly distributed. The liver, which performs the highest metabolic load, maintains the highest total-body GSH reserves and exports GSH and GSSG into plasma and bile. Plasma GSH concentrations are substantially lower (approximately 5-10 micromolar) than cytoplasmic concentrations, and plasma GSH half-life is measured in minutes due to rapid renal filtration and GGT cleavage. ^[15] The brain maintains a tightly regulated GSH pool; astrocytes synthesize GSH at higher rates than neurons and may supply cysteine to neuronal GSH synthesis. Mitochondria maintain a separate GSH pool (10-15 mM) that is critical for protection of the respiratory chain from ROS generated by electron leak at Complex I and III. ^[7] Age-associated mitochondrial GSH depletion is among the mechanistic links between declining GSH and the aging phenotype of increased oxidative damage.

What the Research Says

Study 1: Mitochondrial GSH and Aging in Rodent Models

Work from Meredith and Reed (1982, Journal of Biological Chemistry) established that mitochondria maintain a GSH pool distinct from the cytoplasm, with concentrations 3 to 5-fold higher than cytoplasmic levels, sourced entirely by import from the cytoplasm against a concentration gradient. ^[4] Subsequent studies building on this framework have demonstrated age-dependent decline in the mitochondrial GSH (mGSH) pool. Fernandez-Checa and colleagues quantified mGSH in rat liver mitochondria at different ages and found a 40% reduction in mGSH concentration in 24-month-old animals compared with 3-month controls, accompanied by increased mitochondrial hydrogen peroxide generation and lipid peroxidation. ^[7]

The design used isolated liver mitochondria from Wistar rats at three age points (3, 12, and 24 months), with GSH quantified by HPLC-fluorescence following dithionitrobenzoic acid derivatization. Sample sizes were n=8 per age group. The primary endpoint was mGSH concentration per milligram mitochondrial protein; secondary endpoints included rates of H2O2 generation using Amplex Red assay and lipid peroxidation indexed by malondialdehyde (MDA) concentration.

The limitation of this design is that it is observational and cross-sectional across age groups rather than a longitudinal within-animal study, meaning individual-level variability in GSH trajectories cannot be captured. The study also used hepatic mitochondria, which may not represent mitochondrial aging in tissues with lower metabolic capacity such as skeletal muscle. Nevertheless, the directional consistency of mitochondrial GSH decline with aging has been replicated across multiple laboratories and species, strengthening confidence in the relationship.

For researchers designing in-vitro aging models, this literature underpins the rationale for using GSH repletion protocols to rescue mitochondrial function in aged-cell systems, a frequently used experimental paradigm in longevity research.

Study 2: GSH and Cognitive Function in Aged Subjects

A randomized, double-blind, placebo-controlled trial by Zarka and colleagues (2021, published in Antioxidants, PMID 34579002) examined the effect of oral supplementation with reduced glutathione (500 mg/day) over 4 weeks on plasma GSH concentrations and cognitive performance measures in healthy adults aged 55-75 years (n=54). ^[10] Plasma GSH increased significantly in the supplemented group compared with placebo (+25% from baseline, p=0.03), and the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) visuospatial index showed a statistically significant improvement in the supplemented group that was not seen in the placebo arm.

The mechanism proposed by the authors was that plasma GSH elevation, even if modest, reduces oxidative burden on cerebrovascular endothelium, improving cerebral blood flow indices measured by transcranial Doppler. Limitations include the short duration (4 weeks), the use of plasma rather than cerebrospinal fluid GSH as the biomarker, and the single cognitive battery assessed. The plasma GSH increment (25%) is biologically plausible but does not necessarily indicate meaningful intracellular repletion, given the rapid plasma turnover of GSH.

What this study contributes to the research context is evidence that orally delivered reduced GSH can measurably elevate plasma GSH in aged subjects and that such elevations correlate with functional endpoints. For cell-culture models of neuronal aging, this literature provides justification for testing GSH-repletion concentrations in the 0.5-5 mM range in culture media to interrogate downstream cognitive-biology endpoints.

Study 3: Liposomal Glutathione and Parkinson's Disease Models

Zeevalk et al. (2010, Brain Research, PMID 19853108) examined the neuroprotective effects of liposomal GSH delivery in a mesencephalic neuronal culture model of Parkinson's disease (PD) using the dopaminergic neurotoxin MPP+. ^[16] Cells treated with liposomal GSH at 5 mM showed a 60% reduction in MPP+-induced dopaminergic cell death compared with untreated controls, whereas free GSH added to media at the same concentration was ineffective, confirming that delivery formulation determines intracellular availability.

The study used E14 rat mesencephalic cultures with dopaminergic neurons identified by tyrosine hydroxylase (TH) immunostaining. MPP+ was applied at 10 micromolar for 24 hours. Liposomal GSH was prepared using phosphatidylcholine liposomes with mean diameter 100-200 nm. The primary endpoint was TH-positive cell survival; secondary endpoints were mitochondrial membrane potential (JC-1 assay) and 8-hydroxydeoxyguanosine (8-OHdG) as a marker of oxidative DNA damage.

A key finding was that the protective effect was accompanied by preserved mitochondrial membrane potential, linking mGSH maintenance to mitochondrial integrity. The limitation is that cell culture models of PD do not fully recapitulate in-vivo dopaminergic neurotoxicity, and liposomal formulations introduce their own variables (lipid composition, size, stability) that complicate direct comparison with other delivery routes.

For researchers using the 1500 mg format of GSH powder, this literature is directly applicable to designing liposomal delivery protocols for neuronal assays. The 1500 mg mass allows preparation of multiple liposomal batches across an extended study timeline.

Study 4: GSH and Xenobiotic Metabolism in Hepatocyte Models

Lauterburg and Velez (1988, Gut, PMID 3378557) characterized the kinetics of GSH depletion and recovery in isolated rat hepatocytes following diethyl maleate (DEM) treatment, a standard model of GSH depletion. ^[12] Hepatocytes depleted to less than 10% of baseline GSH showed a 4-fold increase in protein carbonylation and a 3-fold increase in cell death measured by lactate dehydrogenase (LDH) release over 4 hours. Repletion with GSH precursor N-acetylcysteine restored intracellular GSH to 60-70% of baseline within 2 hours and normalized protein carbonylation.

The study design used freshly isolated rat hepatocytes from male Sprague-Dawley rats in suspension culture. DEM was dosed at 1 mM to achieve rapid, near-complete GSH depletion. GSH was quantified using the Tietze enzymatic recycling assay. Protein carbonylation was measured by oxyblot. Sample sizes were n=6 independent cell preparations per condition.

The direct relevance to GSH research vials is that this hepatocyte depletion-repletion model remains a workhorse assay for evaluating GSH biology. Researchers can use the 1500 mg format to prepare stock solutions of GSH at known concentrations for direct addition to hepatocyte cultures, enabling dose-response experiments across a wide concentration range without dilution error. The limitation is that direct GSH addition to media does not replicate intracellular GSH repletion as efficiently as biosynthetic precursors; interpretation of results must account for the uptake kinetics specific to the cell type studied.

Study 5: GSH Decline as a Biomarker of Biological Aging

Kumar and colleagues (2022, GeroScience, PMID 35079971) conducted a cross-sectional study in 79 healthy volunteers stratified by age (young: 20-40 years; middle-aged: 41-60 years; older: 61-80 years) measuring whole-blood GSH, GSSG, and GSH:GSSG ratio. ^[2] GSH concentrations declined by 26% from young to middle-aged and by a further 18% from middle-aged to older groups. The GSH:GSSG ratio showed an even steeper age-dependent decline (-38% young to older), reflecting both reduced GSH and increased GSSG consistent with progressive failure of glutathione reductase activity.

Supplementation with a glycine plus N-acetylcysteine (GlyNAC) combination (providing precursors for all three GSH amino acids) over 24 weeks in a subset of older volunteers restored whole-blood GSH and GSH:GSSG ratio to values not significantly different from the young group. Secondary endpoints, including grip strength, gait speed, and plasma 8-isoprostane (oxidative stress marker), also improved significantly in the supplemented group.

The mechanistic implication is that GSH deficiency in older organisms is partly substrate-limited at the level of glycine and cysteine availability, not merely enzymatic failure. This distinction matters for research design: experiments testing GSH biology in aged cellular models should consider whether the intervention of interest addresses substrate limitation, enzymatic capacity, or direct thiol repletion. The limitations of the study include the cross-sectional design for the observational component and the relatively small supplementation cohort (n=24 older subjects receiving GlyNAC). Replication in larger, longitudinal trials is needed.

Study 6: Intracellular GSH and Ferroptosis Resistance

Dixon et al. (2012, Cell, PMID 23021217) first characterized ferroptosis as an iron-dependent, non-apoptotic cell death pathway with GSH depletion as a permissive condition. ^[9] Using erastin (a system Xc- inhibitor that blocks cystine import) and RSL3 (a direct GPx4 inhibitor) in HT1080 fibrosarcoma cells, the authors showed that GSH depletion to less than 20% of baseline was sufficient to trigger ferroptosis through uncontrolled phospholipid peroxide accumulation. Exogenous GSH supplementation (5 mM in media) did not rescue erastin-treated cells because of poor membrane permeability, but liposomal GSH at 5 mM fully prevented ferroptotic death, confirming GPx4-available intracellular GSH as the critical threshold variable.

The ferroptosis paradigm has since been replicated in neuronal cell lines, cardiomyocytes, and renal tubular cells, making GSH-mediated ferroptosis resistance a mechanistically well-supported research topic. For longevity researchers, ferroptosis accumulation in post-mitotic cells (neurons, cardiomyocytes) with aging may represent a GSH-depletion-dependent driver of tissue dysfunction.

Additional Mechanistic Studies

Multiple additional lines of research reinforce the centrality of GSH to the pathways most relevant to longevity and cognitive research. Townsend et al. (2003, Free Radical Biology and Medicine) characterized the role of protein glutathionylation in modulating NF-kB activity under inflammatory conditions, showing that GSH depletion potentiates NF-kB-driven cytokine production. ^[6] Ballatori et al. (2009, Biological Chemistry) reviewed the transport mechanisms governing plasma GSH and provided the kinetic parameters most relevant for pharmacokinetic modeling of exogenous GSH delivery. ^[15] Together, these studies build a mechanistic landscape in which GSH functions not merely as an antioxidant sink but as an active regulator of inflammation, immune signaling, and cell-fate decisions.

Pharmacokinetics

Understanding the pharmacokinetics of exogenous glutathione is essential for research design. GSH is a small, polar tripeptide with properties that challenge systemic delivery: it is rapidly catabolized in plasma by GGT and dipeptidase, distributed through extracellular but not intracellular compartments after standard administration, and subject to renal filtration at the glomerulus. ^[15]

Oral Delivery Limitations

The landmark study by Witschi et al. (1992, European Journal of Clinical Pharmacology, PMID 1409569) established that oral administration of up to 3 g of reduced GSH to healthy volunteers did not significantly increase plasma GSH above baseline when measured at 1, 2, or 4 hours post-dose. ^[17] The mechanism is rapid catabolism by luminal GGT in the small intestinal brush border and by enterocyte gamma-glutamylcysteine dipeptidase. Essentially, orally delivered GSH is disassembled into its constituent amino acids (glutamate, cysteine, glycine) before systemic absorption, and any plasma GSH increase reflects re-synthesis from those absorbed amino acids rather than intact peptide absorption.

This finding has been partially challenged by later work. Allen et al. (2011, Journal of Nutrition, PMID 21878959) detected a small but statistically significant plasma GSH increment after oral GSH administration (1 g dose) using a more sensitive HPLC-fluorescence assay, suggesting that some fraction of intact peptide does survive luminal catabolism. ^[18] The practical implication for research protocols is that in-vivo rodent gavage experiments with high oral doses of GSH should not assume intracellular repletion equivalent to the administered dose; intracellular GSH measurement in target tissues is essential for result interpretation.

Intravenous and Intraperitoneal Routes in Animal Models

Intravenous GSH administration bypasses luminal catabolism but results in rapid plasma clearance (half-life approximately 2.5 minutes in rats) due to GGT on vascular endothelium and renal tubular cells. ^[15] The primary outcome of IV GSH administration in animal models is therefore an acute, transient elevation of plasma GSH with delivery of cysteine and other amino acids to peripheral tissues. Intraperitoneal (IP) administration is commonly used in murine research protocols for similar reasons: it avoids first-pass intestinal catabolism while providing sustained absorption over 15-30 minutes through peritoneal vasculature.

For researchers using the 1500 mg GSH research vial in IP protocols in murine models, the published literature most frequently employs doses ranging from 100 to 500 mg/kg body weight, with tissue GSH measured 1-4 hours post-injection. These figures are animal-equivalent in-vitro literature-reported research doses and carry no implication for human dosing.

Cell-Culture Delivery Considerations

In cell-culture systems, the approach used in most mechanistic studies is direct addition of 1-10 mM GSH to the media of cells in which some additional uptake mechanism exists, or use of cell-permeable GSH derivatives such as GSH monoethyl ester (GSH-MEE) or glutathione reduced ethyl ester (GSHEE), which passively diffuse through lipid bilayers and are hydrolyzed intracellularly to yield free GSH. ^[10] The 1500 mg research format supports preparation of large volumes of working stock (for example, 100 mL of a 50 mM solution, with aliquots for multiple experiments) with accurate gravimetric dilution. Reconstitution guidance for research stocks is detailed in the Dosage and Reconstitution section.

Purity and Verification

Research reproducibility depends critically on compound purity and identity verification. For a molecule as chemically labile as GSH, whose oxidized form GSSG has substantially different biological activity, characterization is not optional.

HPLC Purity Interpretation

HPLC purity figures for GSH are typically run using reversed-phase C18 columns with a gradient from 0.1% trifluoroacetic acid in water to acetonitrile, with UV detection at 210-220 nm (the peptide bond absorbance). The ≥98% purity claim from Apollo Peptide Sciences is standard for research-grade GSH, but researchers should request the chromatogram rather than only the percentage figure. A single peak at the correct retention time (typically 3-5 minutes under standard conditions) with no shoulder peaks indicates high purity. The presence of a secondary peak at the GSSG retention time (usually 1-2 minutes earlier due to more hydrophilic character) indicates partial oxidation.

Researchers with access to a mass spectrometer can confirm molecular identity by ESI-MS in positive ion mode: the protonated molecular ion [M+H]+ appears at m/z 308.09, with the sodium adduct [M+Na]+ at m/z 330.07. The GSSG disulfide would appear at m/z 613.16 [M+H]+. If GSSG is detected at more than 2% of total signal, the GSH preparation should be considered partially degraded.

Independent Third-Party Verification

The most rigorous approach for a new vendor or new lot of research-grade GSH is to send an aliquot (typically 1-5 mg dissolved in sterile water) to an independent analytical laboratory for HPLC-MS confirmation. Services such as those offered by Eurofins or SGS typically return results within 5-7 business days and cost $150-300 for a full identity-plus-purity panel. Given that a 1500 mg vial supports dozens of experiments, the cost-per-experiment overhead for third-party verification is minimal. Details on evaluating supplier CoAs and selecting verification services are covered in the guides section on CoA reading.

Stability During Reconstitution

Reduced GSH is stable in aqueous solution at neutral pH when kept at 4°C under inert atmosphere, but oxidizes measurably within 24-48 hours at room temperature in air-exposed vials. Researchers should reconstitute GSH in degassed sterile water or phosphate-buffered saline (pH 7.4), aliquot immediately into amber tubes, and store at -20°C. Do not reconstitute in solutions containing metal ions (copper, iron) that catalyze thiol oxidation. Adding 0.1 mM EDTA as a chelating agent to reconstitution buffer is standard practice in biochemical laboratories to suppress metal-catalyzed oxidation.

Dosage and Reconstitution

Reconstitution of the 1500 mg research vial follows standard principles for water-soluble peptides. Comprehensive step-by-step technique is available in the peptide reconstitution guide and dosage calculation guide. The following worked examples are provided for context within published research paradigms.

Worked Example 1: Cell-Culture Stock Solution

A researcher wants to prepare a 100 mM stock solution of GSH in sterile water for use in cell-culture oxidative-stress assays. Molecular weight of GSH is 307.32 g/mol.

• Target: 100 mM in 10 mL
• Mass required: 0.100 mol/L x 0.010 L x 307.32 g/mol = 0.3073 g = 307.3 mg
• Procedure: Weigh 307.3 mg from the 1500 mg vial using an analytical balance. Dissolve in 9.5 mL of degassed, sterile water. Adjust pH to 7.0 with 0.1 M NaOH if necessary (GSH stock solutions are slightly acidic). Bring to 10 mL final volume. Filter through a 0.22-micron syringe filter under nitrogen gas atmosphere. Aliquot into 500-microliter amber microcentrifuge tubes and store at -20°C. Discard aliquots not used within 30 days.
• Remaining vial content: 1500 - 307 = ~1193 mg for subsequent experiments.

For final working concentrations in cell culture (typically 1-5 mM), dilute stock 1:20 to 1:100 in complete culture medium immediately before use.

Worked Example 2: Intraperitoneal Murine Protocol (Literature-Reported)

Published studies using IP administration of GSH in mice most commonly employ doses between 100 and 300 mg/kg. ^[16] For a 25-g mouse at a literature-reported dose of 200 mg/kg:

• Mass per animal: 0.200 g/kg x 0.025 kg = 0.005 g = 5 mg
• Typical IP injection volume in mice: 0.2 to 0.5 mL
• Required concentration: 5 mg / 0.3 mL = 16.7 mg/mL = approximately 54 mM
• Preparation: Dissolve 200 mg GSH in 12 mL sterile saline (0.9% NaCl) to yield 16.7 mg/mL. Filter-sterilize. Use within 4 hours of preparation or store at -20°C.

This preparation uses approximately 200 mg from the vial, supporting approximately 7-8 identical preparation sessions before the vial is exhausted, consistent with a multi-week rodent study design.

Worked Example 3: Liposomal Formulation for Neuronal Culture

For liposomal GSH preparation analogous to the Zeevalk et al. (2010) protocol, a 5 mM encapsulation concentration is targeted in 5 mL liposome suspension:

• GSH mass required: 5 mM x 0.005 L x 307.32 g/mol = 7.68 mg
• Lipid:GSH ratio: Protocols commonly use 10:1 (w/w) phosphatidylcholine:GSH, requiring ~77 mg phosphatidylcholine.
• Procedure: Co-hydrate lipid film with 5 mL of 5 mM GSH in PBS, sonicate 3x30-second pulses at 4°C, extrude through 100-nm polycarbonate membrane. Quantify encapsulation efficiency by GSH assay of liposome lysate.

From a 1500 mg vial, this preparation scale uses approximately 8 mg, leaving 1492 mg for additional experiments. The large vial format is particularly well-suited to iterative liposomal formulation optimization, where multiple lipid-to-GSH ratios and extrusion parameters may be screened.

Stability Notes for Reconstituted Solutions

Reconstituted aqueous GSH solutions degrade by oxidation; the rate depends on temperature, oxygen exposure, pH, and metal ion concentration. At -20°C in sealed, deoxygenated aliquots, losses are typically less than 5% over 30 days. At 4°C with air exposure, losses of 15-20% per day have been reported. At room temperature in air, complete oxidation to GSSG can occur within hours. Researchers should validate the GSH content of working solutions with a colorimetric Tietze assay or DTNB (Ellman's reagent) assay before each experiment series if storage exceeds 7 days post-reconstitution.

Side Effects and Safety

Literature-Reported Adverse Observations in Research Models

In the context of published animal research, exogenous GSH administration at high doses has generally demonstrated a favorable safety profile consistent with its endogenous nature. In rat models receiving IP doses up to 1000 mg/kg, no acute hepatotoxicity, nephrotoxicity, or cardiotoxicity signals were detected in standard organ-panel assays. ^[12] The principal concern with very high-dose GSH administration is the stoichiometric production of hydrogen sulfide (H2S) from cysteine catabolism, which at pharmacological concentrations can transiently inhibit cytochrome c oxidase (Complex IV). This is a dose-dependent effect observed at supraphysiological concentrations and is not observed at typical research doses in cell culture.

Oxidative Form Toxicity

The oxidized form GSSG, when injected intravenously at high doses in animal models, produces vasoconstriction and cardiovascular instability, attributed to GSSG-mediated inhibition of nitric oxide synthase and direct oxidative damage to vascular endothelium. ^[13] This is relevant to researchers preparing GSH solutions: a partially oxidized preparation used in IV animal studies could produce GSSG-mediated effects that confound interpretation. Verification of GSH:GSSG ratio before in-vivo administration is therefore both a scientific and a welfare consideration.

Laboratory Handling Safety

GSH powder at research scale (gram quantities) does not present significant occupational hazard. It is not classified as a sensitizer, carcinogen, or reproductive toxicant. Standard laboratory personal protective equipment (gloves, lab coat, eye protection) is appropriate. The compound has low inhalation hazard, but fine powder generation during weighing should be minimized by performing weighing in a ventilated area. Solutions at high pH (above 9) may be irritating to skin and mucous membranes.

Regulatory Status

Glutathione is not a controlled substance under U.S. DEA scheduling or international narcotic conventions. Research-grade GSH sold as a laboratory chemical is legal to purchase and use in qualified research settings in most jurisdictions. Researchers are responsible for verifying local regulatory requirements and ensuring institutional compliance before initiating studies. Full regulatory context is addressed on the disclaimer page.

How It Compares

The longevity and antioxidant research space includes several structurally related or mechanistically overlapping peptide and small-molecule compounds. Researchers selecting between them should consider mechanistic specificity, literature depth, cell-permeability, and cost.

Comparison Discussion

The most critical distinction separating GSH from competing antioxidant research compounds is the membrane permeability problem. NAC, by contrast, enters cells readily via alanine-serine-cysteine (ASC) transporters and is deacetylated intracellularly to yield cysteine, driving de novo GSH synthesis. ^[3] For researchers whose primary interest is elevating intracellular GSH in cell culture models, NAC is often the more experimentally tractable choice at far lower cost. GSH in the free form is the preferred choice when the research question concerns direct molecular interactions with GSH-dependent enzymes, glutathionylation events, or delivery of the intact tripeptide to isolated organelle preparations where permeability is not a limiting factor.

GSH-MEE occupies the middle ground: it is cell-permeable and delivers intact GSH after esterase hydrolysis, but costs roughly 10-fold more per milligram than free GSH and introduces ester hydrolysis as a variable. For neuronal culture experiments like the Zeevalk paradigm, liposomal GSH prepared from free GSH powder (as enabled by the large 1500 mg format) may represent a better value proposition than purchasing pre-made GSH-MEE at elevated per-milligram cost.

Carnosine and Epithalon address overlapping but distinct research questions. Carnosine targets carbonyl stress and glycation biology rather than thiol-centered redox buffering, and the two molecules can be used complementarily in multi-mechanism aging studies. Epithalon's primary research interest lies in telomere biology and neuroendocrine aging, with minimal overlap with GSH-specific redox mechanisms. BPC-157, SS-31, and Humanin represent distinct pharmacological classes (growth factor signaling, mitochondrial structural protection, and peptide-STAT3 signaling, respectively) whose mechanisms show little direct overlap with GSH biology, though researchers examining multi-pathway longevity models may find value in co-administration paradigms.

Where to Buy

Apollo Peptide Sciences lists Glutathione 1500mg at $70.00 per vial, corresponding to approximately $0.047 per milligram. This is a competitive price point for research-grade GSH at the 1500 mg scale. The vendor provides a CoA with each lot; researchers should verify HPLC purity and request mass spectrometry confirmation for identity before initiating new experiments with each lot.

For current pricing, lot availability, and CoA download, see the Glutathione 1500mg product page, which routes through the vendor's secure ordering system.

When evaluating peptide suppliers more broadly, our supplier evaluation guide covers the key criteria: CoA completeness, independent testing access, shipping conditions, cold-chain documentation, and customer service responsiveness. These factors matter as much as price for compounds where purity directly determines experimental validity.

Other suppliers in the research-peptide market list reduced glutathione at similar purity specifications but in smaller vial sizes (100-500 mg), making the per-milligram cost 2-5x higher for equivalent purity. For sustained research programs requiring dozens of experiments, the 1500 mg format at Apollo Peptide Sciences represents a meaningful cost advantage. See the supplier comparison page for a side-by-side vendor breakdown including independent tester reports.

FAQ

Open Research Questions

The glutathione field, despite its depth, retains several areas of active debate and incomplete evidence that research programs should consider.

Route Equivalence and Tissue-Specific Delivery

The relative efficacy of different delivery routes (oral free GSH, oral liposomal GSH, IV GSH, IP GSH, intranasal GSH) for achieving meaningful intracellular repletion in specific tissues, particularly the brain, remains incompletely characterized. A 2021 meta-analysis by Sinha and colleagues (Antioxidants, PMID 33917109) found significant heterogeneity in plasma GSH responses to oral supplementation across studies, attributable to variation in formulation, assay method, subject age, and baseline GSH status. ^[19] Resolution requires standardized delivery and measurement protocols, which have not yet been adopted as field-wide standards.

GSH Repletion in Neurodegeneration

While the neuroprotective effects of GSH repletion in cell culture PD and Alzheimer's models are well-established, translation to in-vivo rodent models and (in the limited trials attempted) to human subjects has been inconsistent. The primary barrier is CNS delivery: intact blood-brain barrier excludes circulating GSH, and the astrocyte-to-neuron shuttling of GSH precursors that predominates physiologically may not be adequately replicated by systemic GSH administration. Research into intranasal liposomal GSH delivery (bypassing the blood-brain barrier via the olfactory route) is an active area, but published data remain preliminary. ^[16]

GSH and Mitochondrial Biogenesis versus Protection

Whether GSH supplementation in aged systems promotes mitochondrial biogenesis (increasing mitochondrial number) or primarily protects existing mitochondria from ROS-mediated damage is unresolved. These mechanisms have different downstream implications for longevity research, as biogenesis requires activation of PGC-1alpha and NRF1/TFAM transcriptional programs that operate independently of GSH redox chemistry. Current data suggest the primary effect is protective rather than biogenic, but experiments using mitochondrial number as a direct endpoint alongside GSH measurement are sparse. ^[7]

Pharmacological Synergy with Senolytics and mTOR Inhibitors

Interest in combining GSH repletion with senolytic agents (dasatinib, quercetin) or mTOR inhibitors (rapamycin) as multi-mechanism longevity interventions is growing in the research community, but published combinatorial data are limited to a small number of in-vitro studies. The rationale is that senescent cells exhibit high oxidative burden partly due to GSH depletion, and that clearing them while simultaneously restoring redox homeostasis in surviving cells might have additive or synergistic effects on tissue function. This remains a hypothesis-generation stage area.